SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Lotus Pharmaceuticals, Inc. (LTUS) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 35/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — LTUS
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$0.00
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2008 |
$0.54 |
$73.8M |
$12.79M |
17.3% |
| 2009 |
$0.33 |
$56.48M |
$16.43M |
29.1% |
| 2010 |
$0.27 |
$72.7M |
$14.43M |
19.8% |
| 2019 |
$0.00 |
$0.00 |
$-21.83K |
- |
| 2020 |
$0.00 |
$0.00 |
$-6.28K |
- |
| 2021 |
$0.00 |
$0.00 |
$-30.41K |
- |
| 2022 |
$0.00 |
$0.00 |
$-21.11K |
- |
| 2023 |
$0.00 |
$0.00 |
$-18.81K |
- |
| 2024 |
$0.00 |
$0.00 |
$111K |
- |
| 2025 |
$0.00 |
$0.00 |
$-29.03K |
- |
